Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Hincelin‐Mery, A."'
Autor:
Agnes Hincelin‐Mery, Xavier Nicolas, Cathy Cantalloube, Robert Pomponio, Pascale Lewanczyk, Myriam Benamor, Dimitry Ofengeim, Emmanuel Krupka, Jennifer Hsiao‐Nakamoto, Amy Eastenson, Nazem Atassi
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of t
Externí odkaz:
https://doaj.org/article/c0c40af6a8594157bbb4aea061f8bfae
Autor:
Hincelin‐Mery, Agnes1 (AUTHOR) agnes.hincelin‐mery@sanofi.com, Nicolas, Xavier2 (AUTHOR), Cantalloube, Cathy1 (AUTHOR), Pomponio, Robert3 (AUTHOR), Lewanczyk, Pascale4 (AUTHOR), Benamor, Myriam1 (AUTHOR), Ofengeim, Dimitry3 (AUTHOR), Krupka, Emmanuel2 (AUTHOR), Hsiao‐Nakamoto, Jennifer5 (AUTHOR), Eastenson, Amy6 (AUTHOR), Atassi, Nazem3 (AUTHOR)
Publikováno v:
CTS: Clinical & Translational Science. Jan2024, Vol. 17 Issue 1, p1-13. 13p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Signe Hässler, Delphine Bachelet, Julianne Duhaze, Natacha Szely, Aude Gleizes, Salima Hacein-Bey Abina, Orhan Aktas, Michael Auer, Jerôme Avouac, Mary Birchler, Yoram Bouhnik, Olivier Brocq, Dorothea Buck-Martin, Guillaume Cadiot, Franck Carbonnel, Yehuda Chowers, Manuel Comabella, Tobias Derfuss, Niek De Vries, Naoimh Donnellan, Abiba Doukani, Michael Guger, Hans-Peter Hartung, Eva Kubala Havrdova, Bernhard Hemmer, Tom Huizinga, Kathleen Ingenhoven, Poul Erik Hyldgaard-Jensen, Elizabeth C Jury, Michael Khalil, Bernd Kieseier, Anna Laurén, Raija Lindberg, Amy Loercher, Enrico Maggi, Jessica Manson, Claudia Mauri, Badreddine Mohand Oumoussa, Xavier Montalban, Maria Nachury, Petra Nytrova, Christophe Richez, Malin Ryner, Finn Sellebjerg, Claudia Sievers, Dan Sikkema, Martin Soubrier, Sophie Tourdot, Caroline Trang, Alessandra Vultaggio, Clemens Warnke, Sebastian Spindeldreher, Pierre Dönnes, Timothy P Hickling, Agnès Hincelin Mery, Matthieu Allez, Florian Deisenhammer, Anna Fogdell-Hahn, Xavier Mariette, Marc Pallardy, Philippe Broët, ABIRISK consortium
Publikováno v:
PLoS Medicine, Vol 17, Iss 10, p e1003348 (2020)
BackgroundBiopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug
Externí odkaz:
https://doaj.org/article/4a837373673e4bce970064eeadc29077
Autor:
Agnes Hincelin-Mery, Pascale Lewanczyk, Cathy Cantalloube, Xavier Nicolas, Myriam Benamor, Robert Pomponio, Emmanuel Krupka, Dimitry Ofengeim, Amy Eastenson, Li Xiong, Nazem Atassi
Publikováno v:
Thursday, April 27.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eade97b371f83170a794429ea8a1d0f
https://doi.org/10.1212/wnl.0000000000202201
https://doi.org/10.1212/wnl.0000000000202201
Autor:
Laura Magill, Marsilio Adriani, Véronique Berthou, Keguan Chen, Aude Gleizes, Salima Hacein-Bey-Abina, Agnes Hincelin-Mery, Xavier Mariette, Marc Pallardy, Sebastian Spindeldreher, Natacha Szely, David A. Isenberg, Jessica J. Manson, Elizabeth C. Jury, Claudia Mauri
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
An important goal for personalized treatment is predicting response to a particular therapeutic. A drawback of biological treatment is immunogenicity and the development of antibodies directed against the drug [anti-drug antibodies (ADA)], which are
Externí odkaz:
https://doaj.org/article/9291a5574cec46f0b474333af96ce3b4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Delphine Bachelet, Signe Hässler, Cyprien Mbogning, Jenny Link, Malin Ryner, Ryan Ramanujam, Michael Auer, Poul Erik Hyldgaard Jensen, Nils Koch-Henriksen, Clemens Warnke, Kathleen Ingenhoven, Dorothea Buck, Verena Grummel, Andy Lawton, Naoimh Donnellan, Agnès Hincelin-Mery, Dan Sikkema, Marc Pallardy, Bernd Kieseier, Bernard Hemmer, Hans Peter Hartung, Per Soelberg Sorensen, Florian Deisenhammer, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn, Philippe Broët, ABIRISK Consortium
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0162752 (2016)
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospecti
Externí odkaz:
https://doaj.org/article/f42ed773756e4b9bb482310f2683d0bf
Autor:
Caroline Trang, Salima Hacein-Bey Abina, Malin Ryner, Florian Deisenhammer, Manuel Comabella, Abiba Doukani, Philippe Broët, Anna Fogdell-Hahn, Julianne Duhaze, Hans-Peter Hartung, Clemens Warnke, Natacha Szely, Delphine Bachelet, Alessandra Vultaggio, Bernd C. Kieseier, Sebastian Spindeldreher, Olivier Brocq, Poul Erik Hyldgaard-Jensen, Michael Auer, Marc Pallardy, Matthieu Allez, Mary Birchler, Tom W J Huizinga, Yehuda Chowers, Yoram Bouhnik, Dorothea Buck-Martin, Elizabeth C. Jury, Amy Loercher, Dan Sikkema, Aude Gleizes, Tobias Derfuss, Jessica J Manson, Guillaume Cadiot, Claudia Sievers, Michael Khalil, Naoimh Donnellan, Raija L.P. Lindberg, Agnès Hincelin Mery, Badreddine Mohand Oumoussa, Enrico Maggi, Martin Soubrier, Kathleen Ingenhoven, Orhan Aktas, Sophie Tourdot, Xavier Montalban, Maria Nachury, Niek de Vries, Timothy P. Hickling, Christophe Richez, Bernhard Hemmer, Franck Carbonnel, Finn Sellebjerg, Jérôme Avouac, Petra Nytrova, Xavier Mariette, Anna Lauren, Signe Hässler, Pierre Dönnes, Eva Havrdova, Michael Guger, Claudia Mauri
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS Medicine
PLoS Medicine, 17(10). PUBLIC LIBRARY SCIENCE
PLoS Medicine, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
Hässler, S, Bachelet, D, Duhaze, J, Szely, N, Gleizes, A, Hacein-Bey Abina, S, Aktas, O, Auer, M, Avouac, J, Birchler, M, Bouhnik, Y, Brocq, O, Buck-Martin, D, Cadiot, G, Carbonnel, F, Chowers, Y, Comabella, M, Derfuss, T, De Vries, N, Donnellan, N, Doukani, A, Guger, M, Hartung, H-P, Kubala Havrdova, E, Hemmer, B, Huizinga, T, Ingenhoven, K, Hyldgaard-Jensen, P E, Jury, E C, Khalil, M, Kieseier, B, Laurén, A, Lindberg, R, Loercher, A, Maggi, E, Manson, J, Mauri, C, Mohand Oumoussa, B, Montalban, X, Nachury, M, Nytrova, P, Richez, C, Ryner, M, Sellebjerg, F, Sievers, C, Sikkema, D, Soubrier, M, Tourdot, S, Trang, C, Vultaggio, A & ABIRISK Consortium 2020, ' Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease : A prospective multicohort study of the ABIRISK consortium ', PLoS Medicine, vol. 17, no. 10, e1003348 . https://doi.org/10.1371/journal.pmed.1003348
PLoS Medicine, Public Library of Science, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
PLoS Medicine, Vol 17, Iss 10, p e1003348 (2020)
PLoS medicine, 17(10):e1003348. Public Library of Science
Universitat Autònoma de Barcelona
PLoS Medicine
PLoS Medicine, 17(10). PUBLIC LIBRARY SCIENCE
PLoS Medicine, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
Hässler, S, Bachelet, D, Duhaze, J, Szely, N, Gleizes, A, Hacein-Bey Abina, S, Aktas, O, Auer, M, Avouac, J, Birchler, M, Bouhnik, Y, Brocq, O, Buck-Martin, D, Cadiot, G, Carbonnel, F, Chowers, Y, Comabella, M, Derfuss, T, De Vries, N, Donnellan, N, Doukani, A, Guger, M, Hartung, H-P, Kubala Havrdova, E, Hemmer, B, Huizinga, T, Ingenhoven, K, Hyldgaard-Jensen, P E, Jury, E C, Khalil, M, Kieseier, B, Laurén, A, Lindberg, R, Loercher, A, Maggi, E, Manson, J, Mauri, C, Mohand Oumoussa, B, Montalban, X, Nachury, M, Nytrova, P, Richez, C, Ryner, M, Sellebjerg, F, Sievers, C, Sikkema, D, Soubrier, M, Tourdot, S, Trang, C, Vultaggio, A & ABIRISK Consortium 2020, ' Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease : A prospective multicohort study of the ABIRISK consortium ', PLoS Medicine, vol. 17, no. 10, e1003348 . https://doi.org/10.1371/journal.pmed.1003348
PLoS Medicine, Public Library of Science, 2020, 17 (10), pp.e1003348. ⟨10.1371/journal.pmed.1003348⟩
PLoS Medicine, Vol 17, Iss 10, p e1003348 (2020)
PLoS medicine, 17(10):e1003348. Public Library of Science
Background Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f38afd466f71b9ab3ba9e7e10f54091
https://doi.org/10.1371/journal.pmed.1003348
https://doi.org/10.1371/journal.pmed.1003348
Autor:
Tom W J Huizinga, M M J Herenius, Pierre Dönnes, Philippe Broët, Bernard Combe, Marc Pallardy, Sylvie Chollet-Martin, Delphine Bachelet, Anne Musters, Signe Hässler, Paul P. Tak, Florian Deisenhammer, Salima Hacein-Bey-Abina, G. Akdemir, Bruno Fautrel, Jocelyn Quistrebert, Saedis Saevarsdottir, Cyprien Mbogning, Xavier Mariette, Aude Gleizes, Naoimh Donnellan, Agnes Hincelin-Mery, Julie E. Davidson, Martina Johannesson, Carla A. Wijbrandts, Sytske Anne Bergstra, Anna Fogdell-Hahn, Imad Abugessaisa, Niek de Vries
Publikováno v:
Seminars in Arthritis and Rheumatism
Seminars in Arthritis and Rheumatism, WB Saunders, 2019, 48 (6), pp.967-975. ⟨10.1016/j.semarthrit.2018.10.006⟩
Seminars in Arthritis and Rheumatism, 2019, 48 (6), pp.967-975. ⟨10.1016/j.semarthrit.2018.10.006⟩
Seminars in arthritis and rheumatism, 48(6), 967-975. W.B. Saunders Ltd
Seminars in Arthritis and Rheumatism, 48(6), 967-975
Seminars in Arthritis and Rheumatism, WB Saunders, 2019, 48 (6), pp.967-975. ⟨10.1016/j.semarthrit.2018.10.006⟩
Seminars in Arthritis and Rheumatism, 2019, 48 (6), pp.967-975. ⟨10.1016/j.semarthrit.2018.10.006⟩
Seminars in arthritis and rheumatism, 48(6), 967-975. W.B. Saunders Ltd
Seminars in Arthritis and Rheumatism, 48(6), 967-975
International audience; OBJECTIVES:To evaluate the incidence of anti-drug antibody (ADA) occurrences and ADA-related risk factors under adalimumab and infliximab treatment in rheumatoid arthritis (RA) patients.METHODS:The study combined retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5ec919fa780e339b4b923b6b2805d4
https://hal.umontpellier.fr/hal-02566700/file/S0049017218301768.pdf
https://hal.umontpellier.fr/hal-02566700/file/S0049017218301768.pdf
